INMODE LTD (INMD) Stock Fundamental Analysis
USA - NASDAQ:INMD - IL0011595993 - Common Stock
15.45 USD
-0.14 (-0.9%)
Overall INMD gets a fundamental rating of 7 out of 10. We evaluated INMD against 190 industry peers in the Health Care Equipment & Supplies industry. INMD gets an excellent profitability rating and is at the same time showing great financial health properties. INMD may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, INMD could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
INMD had positive earnings in the past year.
INMD had a positive operating cash flow in the past year.
Each year in the past 5 years INMD has been profitable.
In the past 5 years INMD always reported a positive cash flow from operatings.
1.2 Ratios
INMD has a Return On Assets of 25.23%. This is amongst the best in the industry. INMD outperforms 98.42% of its industry peers.
INMD has a Return On Equity of 28.44%. This is amongst the best in the industry. INMD outperforms 97.89% of its industry peers.
INMD has a Return On Invested Capital of 16.27%. This is amongst the best in the industry. INMD outperforms 95.26% of its industry peers.
INMD had an Average Return On Invested Capital over the past 3 years of 22.89%. This is significantly above the industry average of 8.88%.
The last Return On Invested Capital (16.27%) for INMD is well below the 3 year average (22.89%), which needs to be investigated, but indicates that INMD had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.23% | ||
| ROE | 28.44% | ||
| ROIC | 16.27% |
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
1.3 Margins
INMD's Profit Margin of 44.50% is amongst the best of the industry. INMD outperforms 97.89% of its industry peers.
INMD's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 28.54%, INMD belongs to the best of the industry, outperforming 95.26% of the companies in the same industry.
In the last couple of years the Operating Margin of INMD has declined.
With an excellent Gross Margin value of 79.98%, INMD belongs to the best of the industry, outperforming 92.63% of the companies in the same industry.
INMD's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.54% | ||
| PM (TTM) | 44.5% | ||
| GM | 79.98% |
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so INMD is creating value.
Compared to 1 year ago, INMD has less shares outstanding
The number of shares outstanding for INMD has been increased compared to 5 years ago.
INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.85
WACC8.79%
2.3 Liquidity
A Current Ratio of 9.60 indicates that INMD has no problem at all paying its short term obligations.
INMD has a Current ratio of 9.60. This is amongst the best in the industry. INMD outperforms 92.11% of its industry peers.
A Quick Ratio of 8.58 indicates that INMD has no problem at all paying its short term obligations.
The Quick ratio of INMD (8.58) is better than 91.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.6 | ||
| Quick Ratio | 8.58 |
3. Growth
3.1 Past
The earnings per share for INMD have decreased by -4.04% in the last year.
Measured over the past years, INMD shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.97% on average per year.
The Revenue has decreased by -3.61% in the past year.
INMD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.35% yearly.
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
Revenue 1Y (TTM)-3.61%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%
3.2 Future
The Earnings Per Share is expected to grow by 1.56% on average over the next years.
The Revenue is expected to grow by 0.74% on average over the next years.
EPS Next Y-9.82%
EPS Next 2Y-1.69%
EPS Next 3Y1.56%
EPS Next 5YN/A
Revenue Next Year-8.24%
Revenue Next 2Y-1.7%
Revenue Next 3Y0.74%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.13 indicates a reasonable valuation of INMD.
Based on the Price/Earnings ratio, INMD is valued cheaply inside the industry as 96.32% of the companies are valued more expensively.
INMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.57.
INMD is valuated reasonably with a Price/Forward Earnings ratio of 8.98.
INMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. INMD is cheaper than 96.32% of the companies in the same industry.
INMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.09, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.13 | ||
| Fwd PE | 8.98 |
4.2 Price Multiples
98.42% of the companies in the same industry are more expensive than INMD, based on the Enterprise Value to EBITDA ratio.
96.84% of the companies in the same industry are more expensive than INMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.39 | ||
| EV/EBITDA | 2.53 |
4.3 Compensation for Growth
The excellent profitability rating of INMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.35
EPS Next 2Y-1.69%
EPS Next 3Y1.56%
5. Dividend
5.1 Amount
INMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:INMD (10/23/2025, 12:23:39 PM)
15.45
-0.14 (-0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners58.73%
Inst Owner Change0.49%
Ins Owners10.65%
Ins Owner ChangeN/A
Market Cap976.59M
Revenue(TTM)401.56M
Net Income(TTM)178.70M
Analysts72.31
Price Target16.58 (7.31%)
Short Float %6.57%
Short Ratio3.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.54%
Min EPS beat(2)-13.69%
Max EPS beat(2)10.61%
EPS beat(4)2
Avg EPS beat(4)-3.62%
Min EPS beat(4)-20.27%
Max EPS beat(4)10.61%
EPS beat(8)3
Avg EPS beat(8)-6.64%
EPS beat(12)7
Avg EPS beat(12)-0.75%
EPS beat(16)11
Avg EPS beat(16)1.82%
Revenue beat(2)0
Avg Revenue beat(2)-2.62%
Min Revenue beat(2)-2.87%
Max Revenue beat(2)-2.38%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-9.96%
Max Revenue beat(4)0.53%
Revenue beat(8)1
Avg Revenue beat(8)-7%
Revenue beat(12)5
Avg Revenue beat(12)-3.84%
Revenue beat(16)9
Avg Revenue beat(16)-1.49%
PT rev (1m)0%
PT rev (3m)-4.69%
EPS NQ rev (1m)0.84%
EPS NQ rev (3m)-14.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.87%
Revenue NQ rev (1m)1.22%
Revenue NQ rev (3m)-6.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.13 | ||
| Fwd PE | 8.98 | ||
| P/S | 2.43 | ||
| P/FCF | 9.39 | ||
| P/OCF | 9.34 | ||
| P/B | 1.55 | ||
| P/tB | 1.55 | ||
| EV/EBITDA | 2.53 |
EPS(TTM)1.9
EY12.3%
EPS(NY)1.72
Fwd EY11.14%
FCF(TTM)1.65
FCFY10.65%
OCF(TTM)1.65
OCFY10.71%
SpS6.35
BVpS9.94
TBVpS9.94
PEG (NY)N/A
PEG (5Y)0.35
Graham Number20.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.23% | ||
| ROE | 28.44% | ||
| ROCE | 17.86% | ||
| ROIC | 16.27% | ||
| ROICexc | 79.63% | ||
| ROICexgc | 79.63% | ||
| OM | 28.54% | ||
| PM (TTM) | 44.5% | ||
| GM | 79.98% | ||
| FCFM | 25.9% |
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
ROICexc(3y)532.49%
ROICexc(5y)5023.19%
ROICexgc(3y)532.49%
ROICexgc(5y)5023.19%
ROCE(3y)25.13%
ROCE(5y)28.51%
ROICexgc growth 3Y-60.68%
ROICexgc growth 5YN/A
ROICexc growth 3Y-60.68%
ROICexc growth 5YN/A
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
F-Score7
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 81.89% | ||
| Cap/Sales | 0.15% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.67% | ||
| Profit Quality | 58.19% | ||
| Current Ratio | 9.6 | ||
| Quick Ratio | 8.58 | ||
| Altman-Z | N/A |
F-Score7
WACC8.79%
ROIC/WACC1.85
Cap/Depr(3y)144.54%
Cap/Depr(5y)147.73%
Cap/Sales(3y)0.22%
Cap/Sales(5y)0.23%
Profit Quality(3y)91.09%
Profit Quality(5y)96.73%
High Growth Momentum
Growth
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
EPS Next Y-9.82%
EPS Next 2Y-1.69%
EPS Next 3Y1.56%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.61%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%
Revenue Next Year-8.24%
Revenue Next 2Y-1.7%
Revenue Next 3Y0.74%
Revenue Next 5YN/A
EBIT growth 1Y-14.49%
EBIT growth 3Y-12.42%
EBIT growth 5Y13.55%
EBIT Next Year-39.83%
EBIT Next 3Y-11.3%
EBIT Next 5YN/A
FCF growth 1Y-40.81%
FCF growth 3Y-8.8%
FCF growth 5Y16.5%
OCF growth 1Y-40.87%
OCF growth 3Y-8.8%
OCF growth 5Y16.36%